Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | TACR2 | P21452 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | AKT2 | P31751 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21263297 | 0.79 | ADORA1 (0.61) | ADORA1ADORA3ADORA2ANUDT1CSNK2A1 | |
| SCHEMBL3217333 | 0.78 | ADORA1 (0.70) | ADORA1ADORA3ADORA2ASMN1; SMN2HTT | |
| SCHEMBL6300129 | 0.76 | SMN1; SMN2 (0.42) | ADORA1ADORA3ADORA2ANUDT1CSNK2A1 | |
| SCHEMBL7383805 | 0.75 | ADORA1 (0.53) | ADORA1ADORA3ADORA2ASMN1; SMN2HTT | |
| SCHEMBL13544179 | 0.68 | ALDH1A1 (0.47) | ADORA1ADORA3CSNK2A1HTTALDH1A1 | |
| SCHEMBL6494388 | 0.68 | HTT (0.43) | ADORA3CSNK2A1SMN1; SMN2HTTALDH1A1 | |
| SCHEMBL29491160 | 0.68 | ALDH1A1 (0.43) | ADORA1ADORA3ADORA2ACSNK2A1SMN1; SMN2 | |
| SCHEMBL16427445 | 0.68 | ALDH1A1 (0.43) | ADORA1ADORA3ADORA2ACSNK2A1SMN1; SMN2 | |
| SCHEMBL31218454 | 0.68 | HTT (0.43) | ADORA3CSNK2A1SMN1; SMN2HTTALDH1A1 | |
| SCHEMBL6300995 | 0.67 | KDM4E (0.44) | ADORA1ADORA3ADORA2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507484-B2 | Preventive and/or therapeutic agent for neutrophilic inflammatory diseases | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-20070213361-A1 | Preventive and/or therapeutic agent for neutrophilic inflammatory diseases | KYOWA KIRIN CO., LTD. (JP) | 2007-09-13 | — | — | US | disclosed |
| EP-1724271-A1 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR NEUTROPHILIC INFLAMMATION DISEASE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-11-22 | — | — | EP | disclosed |
| US-6911469-B2 | Sulfonamide compounds and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-28 | — | — | US | disclosed |
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-07-25 | — | — | US | disclosed |
| US-6348474-B1 | COMPOUNDS AS ANTIDIABETIC AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| EP-0995742-A1 | SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | PDE2A, PDE3A, PDE12 | ADORA1 307/4885ADORA3 582/4885ADORA2A 507/4885 |
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | PDE2A, PDE3A, PYGM | ADORA1 456/4885ADORA3 472/4885ADORA2A 348/4885 |
| US-20070213361-A1 | Preventive and/or therapeutic agent for neutrophilic inflammatory diseases | MPO, MSR1, NR4A3 | ADORA1 146/4885ADORA3 57/4885ADORA2A 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.